clinical trial · NCT04603924
Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients
NeuroBo Pharmaceuticals Inc.·phase3·completed·n = 49
COVID-19NiclosamidePlacebo
brief summary
Study of ANA001 in Moderate and Severe COVID-19 Patients
started
Oct 7, 2020
primary completion
Feb 16, 2022
completion
Feb 16, 2022
last updated
May 15, 2025
detailed description
This is a 2 part, Phase 2/3 multi-center, double blinded, placebo-controlled study to assess the safety, tolerability, and efficacy of oral niclosamide (ANA001) in moderate and severe hospitalized COVID-19 patients compared to placebo.
official title
A Phase 2/3 Randomized and Placebo-Controlled Study of ANA001 in Moderate and Severe COVID-19 Patients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol